Dicerna Pharmaceuticals

Traded on the St. Petersburg Stock Exchange
Dicerna is a biopharmaceutical company focused on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. It was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Dicerna Pharmaceuticals balance sheet

Report period2016 2017 2018 2019 2020 Q3 21
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Dicerna Pharmaceuticals cash flows

Report period2016 2017 2018 2019 2020 Q3 21 TTM
End date of the reporting period
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Dicerna Pharmaceuticals multipliers

Report period2016 2017 2018 2019 2020 Q3 21 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Dicerna Pharmaceuticals profitability

Report period2016 2017 2018 2019 2020 Q3 21 TTM
ROA
ROE
ROS
EBITDA Margin
Operating margin
Dicerna Pharmaceuticals assets
Dicerna Pharmaceuticals cash flows

Dicerna Pharmaceuticals dividend policy

The company doesn't provide dividends
Dicerna Pharmaceuticals news
28.12.2021
Novo Nordisk completed its acquisition of Dicerna Pharmaceuticals for $3.3 billion, or $38.25 per share.
Source: {source} pictogram novonordisk.com
Pictogram next
18.11.2021
Novo Nordisk acquires Dicerna Pharmaceuticals for $3.3 billion, or $38.25 per share. The deal is scheduled to close in Q4 2021.
Source: {source} pictogram novonordisk.com
Pictogram next
09.11.2021
Dicerna Pharmaceuticals' GAAP loss for 9M 2021 was $87.852 million, up 15.4% from $76.161 million in the previous year. Revenue increased 23.1% to $151.894 million from $123.351 million a year earlier.
Source: {source} pictogram sec.gov
Pictogram next
09.08.2021
Dicerna Pharmaceuticals' GAAP loss for 6M 2021 was $70.78 million, up 30.3% from $54.312 million in the previous year. Revenue increased 19.4% to $88.94 million from $74.476 million a year earlier.
Source: {source} pictogram investors.dicerna.com
Pictogram next
All Dicerna Pharmaceuticals news
General information
Company nameDicerna Pharmaceuticals
Tags#pharmacy, #biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address75 Hayden Avenue Lexington, MA 02421 United States
Mailing address75 Hayden Avenue Lexington, MA 02421 United States
Websiteinvestors.dicerna.com
Information disclosurewww.sec.gov